PatentSafe has been very quick and simple to rollout throughout the Company. Our scientists have found it easy to use and value the ability to organize and compile their research findings. We believe PatentSafe increases our efficiency and contributes value to our product portfolio, while protecting our intellectual property position.
Cheyenne, WY and Bracknell, Berkshire, UK (PRWEB) May 16, 2008
Amphora Research Systems (http://www.amphora-research.com), a key provider of electronic laboratory notebook (ELN) products for the biotech industry, announces the purchase of Amphora's PatentSafe solution for researchers at Functional Genetics - a biotechnology company leveraging innovative science to develop new therapeutics for infectious disease and to improve the quality and efficiency of biologics.
Functional Genetics is using Amphora's PatentSafe solution as a fully-electronic ELN, with digital signatures for legal patent evidence. By using PatentSafe not only do they create secure records for patents but also they have the benefit of a searchable, sharable repository of the company's research.
Manu Kohli from Functional Genetics said, "PatentSafe has been very quick and simple to rollout throughout the Company. Our scientists have found it easy to use and value the ability to organize and compile their research findings. We believe PatentSafe increases our efficiency and contributes value to our product portfolio, while protecting our intellectual property position."
Simon Coles, CTO and co-founder of Amphora, explains: "There's a real need for a practical, approachable ELN solution for the hundreds of small and medium sized Biotechs who need the significant productivity gains that come with an ELN, with full protection for their patents. Most ELN solutions on the market were built to serve the needs of Big Pharma, but PatentSafe is very much designed with them in mind. We have designed the system so that it is a "plug & play" set up, we were able to get Functional Genetics up and running on the system within a couple of hours. Because of the way PatentSafe fitted into the scientists' existing working patterns, rolling out the system was smooth and pain free for both parties."
Thanks to PatentSafe, scientists can work using whatever tools suit their research needs best and still collaborate easily on their projects. Scientists no longer have to 'cut and stick' computer printouts into their traditional bound laboratory notebook, saving typically between 15 minutes to an hour per day. Furthermore, the
entire PatentSafe notebook can be searched and shared with colleagues and all work is fully protected for patent and IP purposes. PatentSafe is quick to learn and affordable to deploy, and can be used in conjunction with traditional paper-based methods or in fully electronic mode using secure digital signatures.
Notes for Editors
Launched in 1996, Amphora Research Systems is one of the world's leading suppliers of electronic laboratory notebooks. Its software products, including PatentSafe, are used around the world by large and small companies, including those in the pharmaceutical and chemical sectors. PatentSafe helps scientists to work better, collaborate easily with each other, and protect their inventions.
In July 2007, Amphora was awarded Frost & Sullivan's Market Penetration award based on its continued success in the ELN market.
For further information, please contact: Jo Worthington, Amphora Research Systems
Tel US: +1 800-221-3916×2029
Tel UK: +44 (0) 845 2300160×2029
Email: jow @ amphora-research.com
About Functional Genetics:
Functional Genetics, Inc. (FGI) uses innovative science to develop new therapeutics for infectious disease. The company has leveraged its proprietary technologies to address medically-relevant and commercially-attractive opportunities. FGI has pioneered the concept of Host-Oriented therapeutics to develop new therapeutics that can be used to prevent or deny viruses the ability to harm the host. These novel antiviral compounds are comparably applicable to a broad-spectrum of different viruses and are anticipated to be insensitive to resistance mechanisms that often negate the effectiveness of conventional antiviral drugs.